Share on LinkedInShare on LinkedIn

ARTICLE · 04 NOVEMBER 2025

Merger Remedies Are Back In Play: Recent Developments

Wiggin and Dana LLP
Wiggin and Dana LLP
Contributor
Wiggin and Dana LLP

Wiggin and Dana LLP

Wiggin and Dana is a full-service law firm of highly talented, creative and experienced lawyers...

View firm profile
Explore more from Wiggin and Dana LLP

Recent merger settlements further confirm that merger remedies are back and indicate the healthcare industry remains a priority for antitrust enforcers.

United StatesAntitrust/Competition Law
Robert M. Langer
Robert M. Langer
Caitlyn Doerr
Caitlyn Doerr
Robert Langer
Robert Langer

Recent merger settlements further confirm that merger remedies are back and indicate the healthcare industry remains a priority for antitrust enforcers.

In July, we published an alert regarding the resolutions of two merger investigations initiated by the Federal Trade Commission (FTC) and the Department of Justice Antitrust Division (DOJ).1 We observed a key shift in enforcement policies under the new Trump administration based on the FTC's settlement of the Synopsys/Ansys merger and the DOJ's settlement of the Keysight/Spirent merger. These settlements effectively marked the revival of merger remedies; an enforcement tool that was strongly disfavored during the prior administration and, until recently, was generally considered off-the-negotiating-table.2 The DOJ has since settled via divestiture the Hewlett Packard/Juniper merger.3

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from